Investigation Report on China Repaglinide Market, 2010-2019

Publisher Name :
Date: 02-Jul-2015
No. of pages: 30

According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.

There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million.??

Entering China after 2000, insulin secretagogues agent is mainly used for the treatment of type 2 diabetes. Currently, there are only 3 kinds available in the Chinese market, namely, nateglinide, repaglinide and mitiglinide. They share the same mechanism of action, that is to say, they lower blood glucose by stimulating the release of insulin from the beta cells. Compared with sulfonylurea, insulin secretagogues agent reports shorter duration of glucoselowering action and lower rate of hypoglycemia.

As an insulin secretagogues agent structured different from sulfonylurea, repaglinide is used to control postprandial hyperglycemia. Developed by Novo Nordisk A/S and BoehringerIngelheim together, it entered the United States in Apr. 1998.

As the first new prandial glucose regulator, repaglinide belongs to the class of benzoic acid derivative. Containing a chiral carbon atom, it has stereoselective activity and can be absorbed well on an empty stomach or not. As repaglinide is expelled from the body with bile after being metabolized by CYP3A4 enzyme system in the liver and only 6% of it is excreted through kidney, it is more suitable for patients with kidney disorders. Hence its advantage in the clinic. In 2000, repaglinide of Novo Nordisk A/S came to be sold in China under the name of Novonorm. According to CRI's market survey, it has few rivals and takes up a market share of about 89% for sales value while its main competitor Hanson Pharmaceutical only occupies less than 11% of the market. The sales value of repaglinide in sample hospitals was about CNY 125 million in 2014 and CAGR during the period of 20052014 reached about 22%.

The market size of repaglinide is expected to keep growing in the next few years in China.

Readers can get at least the following information through this report:


  • market size of repaglinide in China

  • major manufacturers of repaglinide for Chinese market and their market share

  • retail price of repaglinide in Chinese market

  • market outlook of repaglinide in China


The author suggests the following groups of people purchase this report:


  • manufacturers of antidiabetic drugs

  • investors/ research institutions interested in Chinese medicine market

  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Investigation Report on China Repaglinide Market, 2010-2019

Table of Contents

1 Related Concepts of Repaglinide
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Repaglinide in China
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Repaglinide in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Repaglinide in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Repaglinide in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Repaglinide in Chinese Hospitals in 2014
6.1 Novo Nordisk A/S (Denmark)
6.2 Hanson Pharmaceutical
6.3 Tianjin Kangrui Pharmaceutical Co., Ltd
6.4 Beijing Wansheng Pharmaceutical Co., Ltd

7 Major Manufacturers of Repaglinide in Chinese Market, 2010-2014
7.1 Novo Nordisk A/S (Denmark)
7.2 Hanson Pharmaceutical
7.3 Tianjin Kangrui Pharmaceutical Co., Ltd
7.4 Beijing Wansheng Pharmaceutical Co., Ltd

8 Market Outlook of Repaglinide in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

List of Charts

Chart Patent Registration Information of Repaglinide in China
Chart Approval Status of Repaglinide in China
Chart Sales Status of Repaglinide in China, 2010-2014
Chart Sales Value of Repaglinide in China, 2010-2014
Chart Sales Value of Repaglinide by Regions in China, 2010-2014
Chart Sales Value of Repaglinide Tablets in China, 2010-2014
Chart Sales Value of Repaglinide Capsules in China, 2010-2014
Chart Market Share of Major Manufacturers of Repaglinide for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Repaglinide Made by Novo Nordisk A/S, 2010-2014
Chart Sales Value and Market Share of Repaglinide Made by Hanson Pharmaceutical, 2010-2014
Chart Sales Value and Market Share of Repaglinide Made by Tianjin Kangrui Pharmaceutical Co., Ltd, 2010-2014
Chart Price of Repaglinide Made by Novo Nordisk A/S in Some Chinese Cities in 2014
Chart Price of Repaglinide Made by Hanson Pharmaceutical in Some Chinese Cities in 2014
Chart Price of Repaglinide Made by Tianjin Kangrui Pharmaceutical Co., Ltd in Some Chinese Cities in 2014

  • Diabetes & Obesity Drug Development Pipeline Review, 2016
    Published: 01-Dec-2016        Price: US 3995 Onwards        Pages: 560
    The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development. The combi......
  • China Insulin (API & Injection) Market Research Report 2016
    Published: 01-Dec-2016        Price: US 3200 Onwards        Pages: 95
    Notes: Sales, means the sales volume of Insulin (API & Injection) Revenue, means the sales value of Insulin (API & Injection) This report studies Insulin (API & Injection) in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - Novo Nordisk - Eli Lilly - Sanofi-Aventis - Dongbao - Bioton - United Laboratories - Merck......
  • Europe Insulin Glargine Market Report 2016
    Published: 01-Dec-2016        Price: US 3900 Onwards        Pages: 102
    Notes: Sales, means the sales volume of Insulin Glargine Revenue, means the sales value of Insulin Glargine This report studies sales (consumption) of Insulin Glargine in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Sanofi-Aventis - Ganlee - DuPont - Eastman - HE......
  • Global Glucagon Like Peptide-1 (GLP-1) Agonists Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 30-Nov-2016        Price: US 3480 Onwards        Pages: 116
    Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.Scope of the Report:This report focuses on the Glucagon Like Peptide-1 (GLP-1) Agonists in Global market, especially in North America, Europe and Asia-Pacific, South America, Middl......
  • United States Glimepiride Market Report 2016
    Published: 29-Nov-2016        Price: US 3800 Onwards        Pages: 108
    Notes: Sales, means the sales volume of Glimepiride Revenue, means the sales value of Glimepiride This report studies sales (consumption) of Glimepiride in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Sanofi-Aventis - Wanbang Biopharmaceuticals - Cspc Pharmaceutical - Tianan Pharmaceutical - Yangtze River Pharmaceutical Group - Takeda Pharms USA......
  • United States Insulin Drugs Diabetes Therapeutics Market Report 2016
    Published: 28-Nov-2016        Price: US 3800 Onwards        Pages: 109
    Notes: Sales, means the sales volume of Insulin Drugs Diabetes Therapeutics Revenue, means the sales value of Insulin Drugs Diabetes Therapeutics This report studies sales (consumption) of Insulin Drugs Diabetes Therapeutics in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - AstraZeneca - Novartis - Novo Nordisk - Boehringer Ingelheim - Bristol-Myers Squibb......
  • Global Insulin Lispro Sales Market Report 2016
    Published: 25-Nov-2016        Price: US 4000 Onwards        Pages: 127
    Notes: Sales, means the sales volume of Insulin Lispro Revenue, means the sales value of Insulin Lispro This report studies sales (consumption) of Insulin Lispro in Global market, especially in USA, China, Europe, Japan, India and Southeast Asia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Eli Lilly and Company - Gan & Lee Pharmaceuticals - ... ......
  • United States Insulin Glargine Market Report 2016
    Published: 25-Nov-2016        Price: US 3800 Onwards        Pages: 103
    Notes: Sales, means the sales volume of Insulin Glargine Revenue, means the sales value of Insulin Glargine This report studies sales (consumption) of Insulin Glargine in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Sanofi-Aventis - Ganlee - DuPont - Eastman - HEC Pharm - ... Split by product types, with sales, revenue, price, market s......
  • Global Insulin Glargine Market Outlook 2016-2021
    Published: 25-Nov-2016        Price: US 2800 Onwards        Pages: 116
    The Global Insulin Glargine) Industry Report 2015 is a professional and in-depth study on the current state of the Insulin Glargine) Industry. The report provides a basic overview of the Industry including definitions, classifications, applications and Industry chain structure. The Insulin Glargine) market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development Status. Development p......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs